Henlius Presents P-II Clinical Trial (HLX07-ESCC201) Results of HLX07 for the Treatment of Esophageal Squamous Cell Carcinoma at ASCO 2023
Shots:
- The P-II study evaluating HLX07 as monotx. or in combination with Hansizhuang in patients aged 18–75yrs. with LA unresectable, or metastatic ESCC. Patients with no prior systemic antitumor therapy (group A) & failed 1L immuno-CT combination or 2 lines of other systemic antitumor therapy (group B)
- As data cut off Feb 2023, 49 patients enrolled in group A (n=30) & group B (n=19), median follow-up duration was 2.9mos., In groups A & B, ORRs (55.2% & 23.1%) among 42 efficacy evaluable patients; investigator-assessed m-PFS (not reached & 1.5mos.); DCR (74.2% & 38.5%)
- The therapy also showed encouraging antitumor activity with a manageable safety profile, AEs (53.3% & 57.9%) with no drug-related death
Ref: Henlius | Image: Henlius
Related News:- Henlius Reports EMA’s Validation of MAA for Hansizhuang (serplulimab) as 1L Treatment of Extensive-Stage Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
